Michael Cookson, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Progenics Phamaceuticals, Inc. (Lanthues)
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen Pharmaceuticals
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Nonagen Bioscience Corp.
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pacifice Edge Diagnostics
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Prokarium
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    04/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer Healthcare Pharmaceuticals
    Date added:
    Date updated:
    04/02/2024
Return to Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) - English